Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat.

Full Abstract

BACKGROUND: Not just de novo induction of diabetes mellitus, but also the progression of diabetic nephropathy may be enhanced under immunosuppressive therapy after organ transplantation. We evaluated whether sirolimus (SRL) or cyclosporine A (CsA) therapy would be a superior immunosuppressant in streptozotocin-induced diabetic nephropathy. METHODS: Diabetes was induced by intravenous injection of streptozotozin (60 mg/kg body weight) in 26 male Sprague-Dawley rats. Eight days after diabetes induction, animals were divided into three groups, which were treated with placebo (n=8), SRL (n=9), or CsA (n=9). Six nondiabetic placebo-treated rats were included as controls. RESULTS: After 19 weeks of diabetes, SRL significantly decreased fibrosis as assessed by periodic acid Schiff staining and by specific extracellular matrix proteins such as fibronectin and laminin at messenger RNA and protein level compared with the diabetic placebo group. SRL ameliorated renal inflammation, glomerular hypertrophy, and podocyte loss as indicated by morphometric and immunohistological analysis. SRL lowered expression and activity of glomerular transforming growth factor-beta1/2 and vascular endothelial growth factor, all of which are considered central cytokines in the pathogenesis of diabetic nephropathy. In contrast, calcineurin phosphatase inhibition through CsA did not ameliorate any of the features of diabetic nephropathy compared with placebo treatment but slightly aggravated glomerular fibrosis without affecting transforming growth factor-beta1/2 or vascular endothelial growth factor. CONCLUSION: Compared with CsA, SRL by anti-inflammatory, antifibrotic, and podocyte-protective effects clearly seems to be the superior treatment of prevention or amelioration of diabetic nephropathy in the rat.

Author information

Author/s: Wittmann, Sandra (S); Daniel, Christoph (C); Stief, Andrea (A); Vogelbacher, Regina (R); Amann, Kerstin (K); Hugo, Christian (C);

Affiliation: Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Erlangen, Germany.

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal: Transplantation (Transplantation), published in United States. (Language: eng)

Reference: 2009-May; vol 87 (issue 9) : pp 1290-9

Dates: Created 2009/05/08; Completed 2009/07/08;

PMID: 19424027, status: MEDLINE (last retrieved date: 7/24/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Animals
Cyclosporine - therapeutic use
DNA Primers
Diabetes Mellitus, Experimental - immunology
Diabetic Nephropathies - drug therapy; immunology; pathology; prevention & control
Fibronectins - genetics
Immunosuppressive Agents - therapeutic use
Laminin - genetics

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: DNA Primers (0) ; Fibronectins (0) ; Immunosuppressive Agents (0) ; Laminin (0) ; RNA, Messenger (0) ; Vascular Endothelial Growth Factor A (0) ; Sirolimus (53123-88-9) ; Cyclosporine (59865-13-3)

These are the most related articles currently in our database: